David Tyronne Howton - 13 Feb 2026 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Feb 2026, 21:31:11 UTC
Prior SEC filing
06 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kimberly Cornwell as attorney-in-fact for David Tyronne Howton

Key filing fact

David Tyronne Howton filed Form 4 for Solid Biosciences Inc. (SLDB) on 18 Feb 2026.

Key facts

  • This page summarizes David Tyronne Howton's Form 4 filing for Solid Biosciences Inc. (SLDB).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 18 Feb 2026, 21:31.

Change

  • Previous filing in this sequence was filed on 06 Feb 2026.
  • Current net transaction value: -$43,494.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001529297 Primary reporting owner

Howton David T

Relationship
Chief Operating Officer
Address
C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN
Signature
/s/ Kimberly Cornwell as attorney-in-fact for David Tyronne Howton
Signature date
18 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLDB transaction

Common Stock

Options Exercise

Transaction value
Shares
+14,687
Change %
+15%
Price
Shares after
112,546
Date
13 Feb 2026
Ownership
Direct
Footnotes
F1
SLDB transaction

Common Stock

Sale

Transaction value
$43,494
Shares
-7,469
Change %
-6.6%
Price
$5.82
Shares after
105,077
Date
18 Feb 2026
Ownership
Direct
Footnotes
F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLDB transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-14,687
Change %
-33%
Price
$0.000000
Shares after
29,376
Date
13 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
14,687
Exercise price
Footnotes
F1, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Footnote F2

This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Footnote F4

The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .